Akebia Therapeutics (STU:AX9) Tariff Resilience Score: 7/10 (As of Jul. 04, 2026)


STU:AX9 Akebia Therapeutics Inc STU:AX9
47 GF Score
Price €1.08
GF Value €1.13
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Akebia Therapeutics Tariff Resilience Score?

Akebia Therapeutics STU:AX9 +1.31% 47 Tariff Resilience Score is 7 as of Jul. 04, 2026. GuruFocus rates STU:AX9 with a GF Score™ of 47/100 and a GF Value™ of €1.13 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Akebia Therapeutics ranks better than 97.09% on this metric.

Akebia Therapeutics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Akebia Therapeutics has Akebia Therapeutics, a biopharmaceutical company, has moderate tariff exposure. While it imports some raw materials, its primary market is the US. The company has some pricing power and alternative sourcing options.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Akebia Therapeutics might have Highly Resilient.

Akebia Therapeutics  (STU:AX9) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Akebia Therapeutics Tariff Resilience Score Related Terms

STU:AX9 vs TKNO, ORGO, SIGA: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akebia Therapeutics Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Tariff Resilience Score falls into.


STU:AX9
47GF Score
Akebia Therapeutics Inc STU:AX9
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Akebia Therapeutics (STU:AX9) has a Tariff Resilience Score of 7 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Akebia Therapeutics ranks #30 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Akebia Therapeutics' Tariff Resilience Score too high?
Akebia Therapeutics' current Tariff Resilience Score is 7. Based on the distribution chart, Akebia Therapeutics ranks #30 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Akebia Therapeutics has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Tariff Resilience Score compare to TKNO and ORGO?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #30 out of 1030 companies for Tariff Resilience Score. This places Akebia Therapeutics in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Akebia Therapeutics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.13, compared to a current price of €1.08 — trading 4.5% below its estimated fair value. The current Tariff Resilience Score is 7. Akebia Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Tariff Resilience Score is 7 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued. The current stock price of €1.08 is trading 4.5% below its estimated GF Value™ of €1.13. GuruFocus considers Akebia Therapeutics to be Fairly Valued.

Key valuation signals for STU:AX9:

  • Tariff Resilience Score: 7
  • GF Value™: €1.13 vs. price of €1.08 (4.5% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Other Exchanges AKBA:USA
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
47GF Score

Get the complete analysis for STU:AX9

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.08
Price
€1.13
GF Value